Hung‐Chih Hsu
Chang Gung University(TW)China Medical University(TW)Linkou Chang Gung Memorial Hospital(TW)China Medical University Hospital(TW)Chiayi Chang Gung Memorial Hospital(TW)Taipei Medical University(TW)
Publications by Year
Research Areas
Colorectal Cancer Treatments and Studies, Genetic factors in colorectal cancer, Gastric Cancer Management and Outcomes, Cancer Genomics and Diagnostics, Hepatocellular Carcinoma Treatment and Prognosis
Most-Cited Works
- → A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer(2015)157 cited
- → Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients(2016)127 cited
- → Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial(2024)96 cited
- → Overexpression of Lgr5 correlates with resistance to 5-FU-based chemotherapy in colorectal cancer(2013)87 cited
- → Lgr5 promotes cancer stemness and confers chemoresistance through ABCB1 in colorectal cancer(2013)67 cited
- → PTPRT and PTPRD Deleterious Mutations and Deletion Predict Bevacizumab Resistance in Metastatic Colorectal Cancer Patients(2018)